RT Journal Article
SR Electronic
T1 Short-term and Long-Term Healthcare Costs Attributable to diagnosed COVID-19 in Ontario; Canada: A Population-Based Matched Cohort Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.04.24313064
DO 10.1101/2024.09.04.24313064
A1 Sander, Beate
A1 Mishra, Sharmistha
A1 Swayze, Sarah
A1 Sahakyan, Yeva
A1 Duchen, Raquel
A1 Quinn, Kieran
A1 Janjua, Naveed
A1 Sbihi, Hind
A1 Kwong, Jeffrey
YR 2024
UL http://medrxiv.org/content/early/2024/09/04/2024.09.04.24313064.abstract
AB Objectives Estimates of health system costs due to COVID-19, especially for long-term disability (post COVID-19 condition [PCC]) are key to health system planning, but attributable cost data remain scarce. We characterized COVID-19-attributable costs from the health system perspective.Methods Population-based matched cohort study in Ontario, Canada, using health administrative data. To assign attribution to COVID-19, individuals, defined as exposed (positive SARS-CoV-2 PCR test, 01/2020-12/2020) were matched 1:1 to an unexposed individuals (01/2016-12/2018). Historical matching was used to reduce biases due to overall reductions in healthcare during the pandemic and contamination bias. The index date was defined as the first occurrence of positive SARS-CoV-2 PCR test. We used phase-of-care costing to calculate mean attributable per-person costs (2023 CAD), standardized to 10 days, during four phases of illness: pre-index date, acute care, post-acute care (suggestive of PCC), and terminal phase (stratified by early and late deaths). Finally, we estimated total costs at 360 days by combining costs with survival estimates.Results Of 165,838 exposed individuals, 159,817 were matched (mean age 40±20 years, 51% female). Mean (95%CI) attributable 10-day costs per person were $1 ($-4, $6) pre-index, $240 ($231, $249) during acute care, and $18 ($14, $21) during post-acute phases. During the terminal phase, mean attributable costs were $3,928 ($3,471, $4,384) for early deaths and $1,781 ($1,182, $2,380) for late deaths. Hospitalizations accounted for 42% to 100% of total costs. Compared to males, costs among females were lower during the acute care phase, but higher during the post-acute care phase. Mean cumulative per-person cost at 360 days was $2,553 ($2,348, $2,756); females had lower costs ($2,194 [$1,945, $2,446]) than males ($2,921 [$2,602, $3,241]).Conclusions SARS-CoV-2 infection is associated with substantial long-term healthcare costs, consistent with our understanding of the PCC. Understanding phase-specific costs can inform health sector budget planning, future economic evaluations, and pandemic planning.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health (MOH) and the Ministry of Long-Term Care (MLTC). This study also received funding from CIHR (GA4- 177757). This research was supported, in part, by a Tier 1 Canada Research Chair (CRC) in Economics of Infectious Diseases held by Beate Sander (CRC-2022-00362) and a Tier 2 CRC in Mathematical Modelling and Program Science held by Sharmistha Mishra (CRC-950-232643).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University Health Network Research Ethics Board. ICES is a prescribed entity under Ontario's Personal Health Information Protection Act (PHIPA). Section 45 of the PHIPA authorizes the ICES to collect personal health information, without consent, for the purpose of analysis or compiling statistical information with respect to the management of, evaluation or monitoring of the allocation of resources to, or planning for all or part of the health system. Projects that use data collected by ICES under section 45 of PHIPA and use no other data are exempt from the REB review. The use of the data in this project is authorized under Section 45 and approved by the ICES Privacy and Legal Office.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Yes